TY - JOUR
T1 - Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation
T2 - A case-control study
AU - Dispenzieri, Angela
AU - Kyle, Robert A.
AU - Lacy, Martha Q.
AU - Therneau, Terry M.
AU - Larson, Dirk R.
AU - Plevak, Matthew F.
AU - Rajkumar, S. Vincent
AU - Fonseca, Rafael
AU - Greipp, Philip R.
AU - Witzig, Thomas E.
AU - Lust, John A.
AU - Zeldenrust, Steven R.
AU - Snow, Denise S.
AU - Hayman, Susan R.
AU - Litzow, Mark R.
AU - Gastineau, Dennis A.
AU - Tefferi, Ayalew
AU - Inwards, David J.
AU - Micallef, Ivana N.
AU - Ansell, Stephen M.
AU - Porrata, Luis F.
AU - Elliott, Michelle A.
AU - Gertz, Morie A.
PY - 2004/5/15
Y1 - 2004/5/15
N2 - Primary systemic amyloidosia (AL) is a plasma cell dyscrasia resulting in multisystem failure and death. High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) has been associated with higher response rates and seemingly higher overall survival then standard chemotherapy. Selection bias, however, confounds interpretation of these results. We performed a case-match-control study comparing overall survival of 63 AL patients undergoing transplantation with 63 patients not undergoing transplantation. Matching criteria included age, sex, time to presentation, left ventricular ejection fraction, serum creatinine, septal thickness, nerve involvement, 24-hour urine protein, and aerum alkaline phosphatase. According to design, there was no difference between the groups with respect to sex (57% males), age (median, 53 years) left ventricular election fraction (65%), number of patients with peripheral nerve involvement (17%), cardiac interventricular septal wall thickness (12 mm), serum creatinine (1.1 mg/dL [97.24 μmol/L]), and bone marrow plasmacytosis (8%). Sixty-six patients have died (16 cases and 50 controls). For PBSCT and control groups, respectively, the 1-, 2-, and 4-year overall survival rates are 89% and 71%; 81% and 55%; and 71% and 41%. Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL.
AB - Primary systemic amyloidosia (AL) is a plasma cell dyscrasia resulting in multisystem failure and death. High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) has been associated with higher response rates and seemingly higher overall survival then standard chemotherapy. Selection bias, however, confounds interpretation of these results. We performed a case-match-control study comparing overall survival of 63 AL patients undergoing transplantation with 63 patients not undergoing transplantation. Matching criteria included age, sex, time to presentation, left ventricular ejection fraction, serum creatinine, septal thickness, nerve involvement, 24-hour urine protein, and aerum alkaline phosphatase. According to design, there was no difference between the groups with respect to sex (57% males), age (median, 53 years) left ventricular election fraction (65%), number of patients with peripheral nerve involvement (17%), cardiac interventricular septal wall thickness (12 mm), serum creatinine (1.1 mg/dL [97.24 μmol/L]), and bone marrow plasmacytosis (8%). Sixty-six patients have died (16 cases and 50 controls). For PBSCT and control groups, respectively, the 1-, 2-, and 4-year overall survival rates are 89% and 71%; 81% and 55%; and 71% and 41%. Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL.
UR - http://www.scopus.com/inward/record.url?scp=2342591289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2342591289&partnerID=8YFLogxK
U2 - 10.1182/blood-2003-12-4192
DO - 10.1182/blood-2003-12-4192
M3 - Article
C2 - 14739213
AN - SCOPUS:2342591289
SN - 0006-4971
VL - 103
SP - 3960
EP - 3963
JO - Blood
JF - Blood
IS - 10
ER -